Amgen Inc. (AMGN) Stock Analysis
Amgen Inc. (NASDAQ: AMGN) is one of the world's largest independent biotechnology companies, discovering and manufacturing human therapeutics across oncology, cardiovascular, immunology, and bone health. Investors research Amgen for its established product portfolio, dividend yield, and exposure to the aging-population healthcare trend.
Get a full AI research report on AMGN
6-step deep analysis in ~90 seconds. Quick research is free — no signup.
What does Amgen Inc. do?
Amgen discovers, develops, manufactures, and distributes biologic drugs worldwide, with flagship products including Enbrel (rheumatoid arthritis), Repatha (cardiovascular), Prolia (osteoporosis), and KYPROLIS (multiple myeloma). The company generates revenue through direct sales of these therapeutics to healthcare systems, insurers, and patients, with a gross margin of 71.4% reflecting the high-margin nature of specialty pharmaceuticals. Patent cliffs and biosimilar competition represent ongoing pressures on mature product revenues, requiring continuous innovation and pipeline advancement.
Bull case
- ✓Strong gross margin of 71.4% and operating margin of 33.8% demonstrate pricing power and operational efficiency typical of established biotech firms with differentiated products.
- ✓Forward P/E ratio of 15.5x is notably lower than the trailing P/E of 25.3x, suggesting market expectations for earnings growth that could support valuation if the pipeline delivers.
- ✓Dividend yield of 2.77% with a payout ratio of 67.2% indicates the company returns capital to shareholders while retaining earnings for R&D and acquisitions.
- ✓Diversified therapeutic portfolio across multiple disease areas and geographies reduces dependence on any single product and provides defensive characteristics in healthcare.
Bear case
- ✗High debt-to-equity ratio of 623.8% reflects significant leverage, which constrains financial flexibility and increases refinancing risk in a rising interest-rate environment.
- ✗Return on equity of 1.01% is exceptionally low relative to the company's market valuation, indicating inefficient capital deployment or substantial intangible asset write-downs.
- ✗Patent expirations and biosimilar competition threaten revenues from legacy products like Enbrel and Neulasta, requiring successful new product launches to offset declines.
- ✗Current ratio of 1.26x and quick ratio of 0.85x suggest moderate liquidity constraints, with the quick ratio below 1.0x indicating potential near-term cash flow pressure.
AMGN valuation & financial health
Amgen trades at a trailing P/E of 25.3x but a forward P/E of 15.5x, with a PEG ratio of 1.99 suggesting moderate valuation relative to expected earnings growth. The company's price-to-book ratio of 21.3x and EV/EBITDA of 14.3x are consistent with a mature, profitable biotech firm. However, the 1.01% return on equity is a significant red flag—it suggests that despite strong margins and profitability, the company's equity base is either inflated by goodwill and intangibles or burdened by high debt. The 623.8% debt-to-equity ratio confirms substantial leverage, which warrants monitoring given the company's reliance on cash flows to service debt and fund R&D.
The bottom line
Amgen presents a mixed profile for investors to weigh. The company's established market position, strong operating margins, and diversified product portfolio offer stability, while the forward P/E discount and dividend yield appeal to value-oriented investors. However, the exceptionally low ROE, high leverage, and patent cliff risks require careful consideration of the company's ability to grow earnings and reduce debt over time. Key factors to monitor include pipeline progress, biosimilar competition timelines, and management's capital allocation strategy—particularly debt reduction versus shareholder returns.
Frequently asked questions
What does Amgen Inc. do?
Amgen discovers, develops, manufactures, and distributes biologic drugs for diseases including rheumatoid arthritis, cardiovascular disease, osteoporosis, cancer, and gout. The company operates globally and sells directly to healthcare systems, insurers, and patients through its specialty pharmaceutical portfolio.
Is AMGN overvalued or undervalued?
Amgen's trailing P/E of 25.3x appears elevated, but the forward P/E of 15.5x suggests the market is pricing in earnings growth. Valuation depends on whether the company's pipeline can offset patent cliff losses and whether leverage can be reduced—both uncertain factors that investors should evaluate independently.
Does Amgen pay a dividend?
Yes, Amgen pays a dividend with a yield of 2.77% and a payout ratio of 67.2%, meaning the company distributes roughly two-thirds of earnings to shareholders while retaining capital for R&D and debt service.
What are the main risks for AMGN stock?
Key risks include patent expirations and biosimilar competition on legacy products, high debt levels (debt-to-equity of 623.8%), and weak return on equity (1.01%), which raises questions about capital efficiency and earnings quality.
How does Amgen compare to other biotech companies?
Amgen is one of the largest independent biotech firms by market cap, with a more mature, diversified product portfolio and higher margins than smaller biotech peers, but faces greater patent cliff risk and leverage than some competitors.
What is Amgen's competitive advantage?
Amgen's competitive advantages include a portfolio of differentiated biologic drugs with strong pricing power, established manufacturing and distribution infrastructure, and a large R&D budget; however, these are offset by patent expirations and the rise of biosimilar competition.
Research AMGN with AI in seconds
Company profile, financials, events, competition, risks and synthesis — automated.
Start free — no signupFor informational purposes only — not investment advice. Analysis is AI-generated from public data and may contain errors. Always do your own research.